Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma

Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma

Abstract Novel perioperative strategies are needed to reduce recurrence rates in patients undergoing nephrectomy for high-risk, non-metastatic clear cell renal cell carcinoma (ccRCC). We conducted a prospective, phase I trial of neoadjuvant nivolumab prior to nephrectomy in 15 evaluable patients wit...

Full description

Bibliographic Details
Main Authors: Nirmish Singla, Thomas R. Nirschl, Aleksandar Z. Obradovic, Eugene Shenderov, Kara Lombardo, Xiaopu Liu, Alice Pons, Jelani C. Zarif, Steven P. Rowe, Bruce J. Trock, Hans J. Hammers, Trinity J. Bivalacqua, Phillip M. Pierorazio, Julie S. Deutsch, Tamara L. Lotan, Janis M. Taube, Yasser M. A. Ged, Michael A. Gorin, Mohamad E. Allaf, Charles G. Drake
Format: Article
Language:English
Published: Nature Portfolio 2024-01-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-024-51889-9

Internet

https://doi.org/10.1038/s41598-024-51889-9

Similar Items